Evidence map›Paper›PMID 38494551›Full record

ReviewAnnals of hematology2024

The application of JAK inhibitors in the peri-transplantation period of hematopoietic stem cell transplantation for myelofibrosis.

Zerong Wang, Xuelian Jin, Jiajia Zeng, Zilin Xiong, Xinchuan Chen

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Annals of hematology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Zerong WangWest China Hospital, Sichuan University, Chendu, Sichuan, China.
Xuelian JinWest China Hospital, Sichuan University, Chendu, Sichuan, China.
Jiajia ZengWest China Hospital, Sichuan University, Chendu, Sichuan, China.
Zilin XiongWest China Hospital, Sichuan University, Chendu, Sichuan, China.
Xinchuan ChenWest China Hospital, Sichuan University, Chendu, Sichuan, China. xinchuan_chen@163.com.
West China Hospital of Sichuan University · CNSichuan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Myelofibrosis (MF) is a myeloproliferative neoplasm (MPN) with a poor prognosis, and allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only treatment with curative potential. Ruxolitinib, a JAK1/2 inhibitor, has shown promising results in improving patients' symptoms, overall survival, and quality of life, and can be used as a bridging therapy to HSCT that increases the proportion of transplantable patients. However, the effect of this and similar drugs on HSCT outcomes is unknown, and the reports on their efficacy and safety in the peri-transplantation period vary widely in the published literature. This paper reviews clinical data related to the use of JAK inhibitors in the peri-implantation phase of hematopoietic stem cell transplantation for primary myelofibrosis and discusses their efficacy and safety.

Indexed as

Hematopoietic Stem Cell TransplantationJanus Kinase InhibitorsNitrilesPrimary MyelofibrosisPyrazolesPyrimidinesAllograftsHumansJanus Kinase 1Janus Kinase 2Janus Kinase 1Janus Kinase 2Janus Kinase InhibitorsNitrilesPyrazolesPyrimidinesruxolitinibAllogeneic hematopoietic stem cell transplantationGraft-versus-host diseaseJAK inhibitorsMyelofibrosisPoor implantationRuxolitinib

Identifiers

PMID38494551
PMCPMC11358344
OpenAlexW4393095170

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.